

Zolgensma

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
specialty:	NP1#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🗖 Same as Requesting Pro	
Name:	NPI#:
Fax:	Phone:
<u>Rendering</u> Provider Info: Same as Referring Prov Name:	
Fax:	NPI#: Phone:
	nits in accordance with FDA-approved labeling, r evidence-based practice guidelines.
Patient Weight:kg	
Patient Height:cm	
Please indicate the place of service for the requested dr Ambulatory Surgical (POS Code 24) Off Campus Outpatient Hospital (POS Code 19) Office (POS Code 11)	\Box Home (POS Code 12)
Drug Information:	
Strength/Measure	
	Route of administration
Dosing frequency	
What is the ICD-10 code?	
Criteria Questions:	
1. What is the diagnosis?	
□ Spinal muscular atrophy (SMA), <i>Continue to 2</i>	
□ Other, please specify.	_, Continue to 2
 2. Does the patient have a genetically confirmed diagn □ Yes, <i>Continue to 3</i> □ No, <i>Continue to 3</i> 	

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Zolgensma SGM 3093-A – 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org



3. Does the patient have bi-allelic mutations in the survival motor neuron 1 (SMN1) gene (deletions or point mutations)? *ACTION REQUIRED*: If Yes, attach genetic testing results demonstrating bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

G Yes ACTION REQUIRED: Submit supporting documentation, Continue to 4

□ No, *Continue to 4*

Unknown, Continue to 4

4. What is the patient's age?

years old, Continue to 5

5. Please select which, if any, of the following indicators of advanced spinal muscular atrophy (SMA) the patient has.

Complete paralysis of limbs, *Continue to 6*

□ Invasive ventilatory support (tracheostomy), *Continue to 6*

□ Respiratory assistance for 16 or more hours per day (including non-invasive respiratory support) continuously for 14 or more days in the absence of acute reversible illness (excluding perioperative ventilation), *Continue to 6*

□ Other indicator(s) of advanced SMA, *Continue to 6*

D Patient does not have any indicators of advanced SMA, Continue to 6

6. Is patient's anti-adeno-associated virus 9 (AAV9) antibody titer less than or equal to 1:50 as determined by an enzyme-linked immunosorbent assay (ELISA) binding immunoassay?

□ Yes, *Continue to 7* □ No. *Continue to 7*

7. Is the medication prescribed by or in consultation with a physician who specializes in treatment of spinal muscular atrophy?

 \square Yes, *Continue to 8*

 \square No, *Continue to 8*

8. Has the patient previously received the requested drug?

□ Yes, Continue to 9

□ No, *Continue to 9*

9. Is the patient currently receiving therapy with nusinersen (Spinraza) or risdiplam (Evrysdi)? If Yes, indicate the date of last dose.

Yes, please specify date of last dose.	(MM/DD/YY), Continue to 10
--	----------------------------

□ No, Continue to 11

10. Will nusinersen (Spinraza) or risdiplam (Evrysdi) be discontinued prior to administration of the requested drug?
Types, *Continue to 11*

□ No, Continue to 11

11. Please indicate the anticipated date of administration of the requested medication.

□ Indicate the date of administration: _____ (MM/DD/YY), No Further Questions

Date unavailable, *No Further Questions*

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Zolgensma SGM 3093-A – 10/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org



I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

Х

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Zolgensma SGM 3093-A – 10/2023. Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.hopkinshealthplans.org

Page 3 of 3